SCHEMBL418364

SCHEMBL418364

COC(=O)c1cc(Cl)ccc1NC(=O)C=Cc1cccc(-c2cccc3cccnc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.54
PPARG P37231 1/20 0.50
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HDAC4 P56524 1/20 0.44
MEF2D Q14814 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
MMP1 P03956 3/20 0.44
MMP2 P08253 3/20 0.44
MMP9 P14780 3/20 0.44
KDR P35968 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418363 1.00 SERPINE1 (0.54) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL417700 0.90 SERPINE1 (0.56) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL417699 0.90 SERPINE1 (0.56) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418644 0.89 SERPINE1 (0.55) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418643 0.88 SERPINE1 (0.69) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL418645 0.88 SERPINE1 (0.69) SERPINE1PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL417435 0.83 ALDH1A1 (0.47) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL417436 0.83 ALDH1A1 (0.47) NPC1RAB9ASMN1; SMN2LMNAALDH1A1
SCHEMBL420831 0.83 EGFR (0.57) SERPINE1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL420830 0.83 EGFR (0.57) SERPINE1NPC1RAB9ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PPARG 2361/4885NPC1 893/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PPARG 2361/4885NPC1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.